WO2006134195A3 - Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa - Google Patents

Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa Download PDF

Info

Publication number
WO2006134195A3
WO2006134195A3 PCT/ES2006/000353 ES2006000353W WO2006134195A3 WO 2006134195 A3 WO2006134195 A3 WO 2006134195A3 ES 2006000353 W ES2006000353 W ES 2006000353W WO 2006134195 A3 WO2006134195 A3 WO 2006134195A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
alpha
cytokine
family
combined administration
Prior art date
Application number
PCT/ES2006/000353
Other languages
English (en)
French (fr)
Other versions
WO2006134195A2 (es
WO2006134195A8 (es
Inventor
Arregui Rafael Aldabe
Leoz Esther Larrea
Murillo Maria Pilar Civeira
Valtuena Jesus Prieto
Original Assignee
Proyecto Biomedicina Cima Sl
Arregui Rafael Aldabe
Leoz Esther Larrea
Murillo Maria Pilar Civeira
Valtuena Jesus Prieto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP06794028A priority Critical patent/EP1905447A4/en
Priority to US11/922,221 priority patent/US7829077B2/en
Priority to CN2006800299002A priority patent/CN101257918B/zh
Priority to BRPI0611988-3A priority patent/BRPI0611988A2/pt
Priority to MX2007016060A priority patent/MX2007016060A/es
Priority to AU2006258966A priority patent/AU2006258966B8/en
Application filed by Proyecto Biomedicina Cima Sl, Arregui Rafael Aldabe, Leoz Esther Larrea, Murillo Maria Pilar Civeira, Valtuena Jesus Prieto filed Critical Proyecto Biomedicina Cima Sl
Priority to CA2612282A priority patent/CA2612282C/en
Priority to JP2008516350A priority patent/JP5154412B2/ja
Publication of WO2006134195A2 publication Critical patent/WO2006134195A2/es
Publication of WO2006134195A3 publication Critical patent/WO2006134195A3/es
Publication of WO2006134195A8 publication Critical patent/WO2006134195A8/es
Priority to US12/887,843 priority patent/US20110027224A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)

Abstract

La presente invención se refiere al uso de al menos una citoquina de la familia IL- 6 -familia gp130 -, preferentemente seleccionada entre la IL-11, el factor inhibidor de la leucemia (LIF) , oncostatina M (OSM) , cardiotrof ina-1, factor neurotrófico ciliar (CNTF) , la citoquina semejante a la cardiotrof ina (CLC) , y combinaciones de ellas, o una secuencia de ADN que la codifica, en la preparación de una composición farmacéutica para la administración combinada con al menos un interferón-alfa o una secuencia de ADN que lo codifica, en el tratamiento de enfermedades virales,- a una composición farmacéutica que comprende una cantidad farmacéuticamente aceptable de al menos una citoquina de la familia IL-6 - familia gp130 -, o una secuencia de ADN que la codifica, y una cantidad farmacéuticamente aceptable de al menos un interferón-alfa, o una secuencia de ADN que lo codifica, a un kit farmacéutico y a un método para tratar enfermedades virales mediante la administración combinada de las citoquinas mencionadas y el interferón-alfa.
PCT/ES2006/000353 2005-06-16 2006-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa WO2006134195A2 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US11/922,221 US7829077B2 (en) 2005-06-16 2006-06-16 Treatment of hepatitis C with compositions comprising oncostatin M and interferon alpha
CN2006800299002A CN101257918B (zh) 2005-06-16 2006-06-16 来自白介素-6家族的细胞因子在用于与干扰素-α组合施用的组合物的制备中的用途
BRPI0611988-3A BRPI0611988A2 (pt) 2005-06-16 2006-06-16 uso de pelo menos um citoquina da famìlia il-6 famìlia gp130, composição farmacêutica, kit farmacêutico e método para o tratamento de uma enfermidade viral
MX2007016060A MX2007016060A (es) 2005-06-16 2006-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
AU2006258966A AU2006258966B8 (en) 2005-06-16 2006-06-16 Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha
EP06794028A EP1905447A4 (en) 2005-06-16 2006-06-16 USE OF A CYTOKIN OF THE INTERLEUKIN 6 FAMILY FOR THE PREPARATION OF A CONNECTION TO COMBINED DISPERSION WITH INTERFERON ALPHA
CA2612282A CA2612282C (en) 2005-06-16 2006-06-16 Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha
JP2008516350A JP5154412B2 (ja) 2005-06-16 2006-06-16 インターフェロンアルファとの組み合わせ投与のための組成物の調製における、インターロイキン６ファミリーサイトカインの使用
US12/887,843 US20110027224A1 (en) 2005-06-16 2010-09-22 Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200501468 2005-06-16
ES200501468A ES2302402B1 (es) 2005-06-16 2005-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/887,843 Division US20110027224A1 (en) 2005-06-16 2010-09-22 Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha

Publications (3)

Publication Number Publication Date
WO2006134195A2 WO2006134195A2 (es) 2006-12-21
WO2006134195A3 true WO2006134195A3 (es) 2007-04-19
WO2006134195A8 WO2006134195A8 (es) 2008-01-31

Family

ID=37532659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2006/000353 WO2006134195A2 (es) 2005-06-16 2006-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa

Country Status (11)

Country Link
US (2) US7829077B2 (es)
EP (1) EP1905447A4 (es)
JP (1) JP5154412B2 (es)
CN (1) CN101257918B (es)
AU (1) AU2006258966B8 (es)
BR (1) BRPI0611988A2 (es)
CA (1) CA2612282C (es)
ES (1) ES2302402B1 (es)
MX (1) MX2007016060A (es)
RU (1) RU2413529C2 (es)
WO (1) WO2006134195A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022952B1 (ru) * 2008-07-23 2016-03-31 Тамара Александровна ВИТКАЛОВА Способ лечения вирусных гепатитов b и c
JP2010059081A (ja) * 2008-09-02 2010-03-18 Okayama Univ オンコスタチンｍを含有する抗ｈｃｖ剤およびその利用
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
US20120308517A1 (en) * 2010-02-09 2012-12-06 Digna Biotech, S.L. Compositions for the treatment of infectious and tumoural diseases
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2018178215A1 (en) 2017-03-31 2018-10-04 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (nmsc)
CN113197910B (zh) * 2021-05-14 2022-09-23 苏州大学 一种基于阿司匹林及其代谢产物提高干扰素抗病毒活性的抗病毒药盒

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2006776A6 (es) * 1986-07-08 1989-05-16 Genetics Inst Un procedimiento para producir una proteina il-6.
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
EP1001801B1 (fr) * 1997-08-04 2002-01-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant au moins un arn double brin en association avec au moins un interferon pour le traitement de l'hepatite virale
EP0858343B1 (en) * 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
ES2224246T3 (es) * 1996-05-13 2005-03-01 F. Hoffmann-La Roche Ag Uso de composiciones sinergeticas de il-12 y inf-alfa para el tratamiento de enfermedadesinfecciosas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348191B1 (en) 1986-07-08 2002-02-19 Genetics Institute, Inc. Production and use of IL-6
US6284237B1 (en) 1986-07-08 2001-09-04 Steven C. Clark Methods of treatment using IL-6
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
EP2298900A1 (en) * 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
ES2200646B1 (es) * 2001-09-21 2005-05-01 Fundacion Para La Investigacion Medica Aplicada Uso de la cardiotrofina en enfermedades hepaticas.
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
US20050027110A1 (en) * 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2006776A6 (es) * 1986-07-08 1989-05-16 Genetics Inst Un procedimiento para producir una proteina il-6.
EP0858343B1 (en) * 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
ES2224246T3 (es) * 1996-05-13 2005-03-01 F. Hoffmann-La Roche Ag Uso de composiciones sinergeticas de il-12 y inf-alfa para el tratamiento de enfermedadesinfecciosas.
EP1001801B1 (fr) * 1997-08-04 2002-01-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant au moins un arn double brin en association avec au moins un interferon pour le traitement de l'hepatite virale
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10

Also Published As

Publication number Publication date
WO2006134195A2 (es) 2006-12-21
EP1905447A2 (en) 2008-04-02
ES2302402A1 (es) 2008-07-01
RU2008100307A (ru) 2009-07-27
US7829077B2 (en) 2010-11-09
AU2006258966B8 (en) 2011-12-08
CA2612282A1 (en) 2006-12-21
RU2413529C2 (ru) 2011-03-10
US20090130055A1 (en) 2009-05-21
WO2006134195A8 (es) 2008-01-31
JP2008546672A (ja) 2008-12-25
AU2006258966A1 (en) 2006-12-21
EP1905447A4 (en) 2012-04-25
MX2007016060A (es) 2008-03-10
JP5154412B2 (ja) 2013-02-27
CN101257918B (zh) 2011-09-21
CA2612282C (en) 2014-03-25
AU2006258966B2 (en) 2011-11-17
CN101257918A (zh) 2008-09-03
ES2302402B1 (es) 2009-05-08
US20110027224A1 (en) 2011-02-03
BRPI0611988A2 (pt) 2010-10-13

Similar Documents

Publication Publication Date Title
WO2006134195A8 (es) Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa
WO2005051317A3 (en) Substituted imidazo ring systems and methods
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2005018551A3 (en) Oxime substituted imidazo-containing compounds
WO2007038703A3 (en) Il-17a and il-17f antagonists and methods of using the same
NO20054959D0 (no) Fremgangsmater for behandling av interleukin-6 relaterte sykdommer
WO2006026760A3 (en) 1-amino imidazo-containing compounds and methods
EP2311488A3 (en) Vaccine composition
EP2684555A3 (en) Use of ceramics in dental and orthodontic applications
WO2005051324A3 (en) Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
UA96922C2 (en) Il-12/p40 binding protein
WO2007147019A3 (en) Il-17 and il-23 antagonists and methods of using the same
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2005018555A3 (en) Lipid-modified immune response modifiers
JP2008546672A5 (es)
WO2001004271A3 (en) Respiratory syncytial viruses expressing immune modulatory molecules
MXPA04006049A (es) Proteina secretada.
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
EA201100322A8 (ru) Интерферон и любой агент, индуцирующий ингибирование протеинфосфатазы 2а, например интерлейкин-1 и по выбору рибавирин, для лечения гепатитов b или c
GB0119015D0 (en) A fusion protein
SG10201906327TA (en) Immunosuppressive composition for use in treating immunological disorders
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
EP4092047A4 (en) PEGYLATED DISUBSTITUTED INTERLEUKIN 2, METHOD FOR PREPARING IT AND ITS USE
AU2016202280A1 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
NO20056089L (no) Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/016060

Country of ref document: MX

Ref document number: 2612282

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008516350

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006794028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5088/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006258966

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008100307

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2006258966

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006258966

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680029900.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06794028

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006794028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11922221

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0611988

Country of ref document: BR

Kind code of ref document: A2